Clinical Guides
Ovarian Cancer — Recognition and Referral
A clinically focused guide to recognising suspected ovarian malignancy, arranging proportionate investigation and referral, and understanding specialist staging and treatment in India without treating a biomarker or foreign threshold as a universal national protocol.
MedNext Academy | 13 min read
Ovarian Cancer — Recognition and Referral
A clinically focused guide to recognising suspected ovarian malignancy, arranging proportionate investigation and referral, and understanding specialist staging and treatment in India without treating a biomarker or foreign threshold as a universal national protocol.
Summary
Ovarian cancer is not one disease. Epithelial cancers, including high-grade serous carcinoma, account for most adult malignant ovarian tumours; fallopian-tube and primary peritoneal high-grade serous cancers share biology and management. Germ-cell and sex-cord stromal tumours are less common and follow different marker and treatment pathways. Many high-grade serous cancers are thought to arise in the distal fallopian tube and spread early across peritoneal surfaces. This helps explain why symptoms can be vague and why apparently ovarian disease is often advanced when diagnosed.
Persistent abdominal distension, early satiety, pelvic or abdominal pain, urinary frequency, unexplained weight loss, ascites or a new complex adnexal mass should trigger structured evaluation. Clinical examination, serum CA125 in the appropriate pathway, pelvic ultrasonography and specialist cross-sectional imaging each answer different questions; no single result confirms or excludes malignancy. Tissue diagnosis and formal staging determine treatment. Avoid aspirating or rupturing a suspicious mass outside an oncology plan.
Management belongs in a gynaecological cancer multidisciplinary team. It may include specialist cytoreductive and staging surgery, platinum-based chemotherapy, biomarker-directed maintenance or recurrent-disease treatment, supportive care and genetics assessment. The sequence depends on fitness, resectability, histology, stage, molecular findings and patient priorities. This educational draft does not prescribe an anticancer regimen, and it remains quarantined following MedNext Clinical Team review.
How Common Is It?
The IARC Global Cancer Observatory's GLOBOCAN 2024 India fact sheet estimates 45,566 new ovarian-cancer cases and 28,782 deaths in India in 2024. Ovary ranked fourth among cancers in females by incident case count and was among the leading causes of female cancer mortality. These are modelled population estimates, not a clinic prevalence study or a forecast of an individual's outcome. Registry coverage, diagnostic access, population structure and modelling uncertainty must be considered when interpreting them. The fact sheet should be quoted with its year because cancer estimates are revised.
Risk and tumour type vary strongly with age. Epithelial tumours predominate in later adulthood, whereas germ-cell tumours have greater relative importance in adolescents and young adults. Within epithelial disease, high-grade serous carcinoma is the dominant aggressive subtype and commonly presents after peritoneal dissemination. An ovarian mass in a young person is therefore not managed by simply copying a postmenopausal CA125 pathway.
India's burden is not evenly distributed. Access to expert ultrasound, pathology, genetic testing and a gynaecological oncologist differs between districts and between public, charitable and private systems. Late presentation may reflect symptom non-specificity, competing family responsibilities, travel cost and fragmented referral rather than biological delay alone. Population burden justifies better recognition and referral, but it does not support screening average-risk asymptomatic people with CA125 or ultrasound: available tests have insufficient predictive performance for that use.
Risk Factors
The strongest clinical risk clues are increasing age, a personal or family history suggesting hereditary breast-ovarian cancer, and a pathogenic variant in BRCA1, BRCA2 or another ovarian-cancer susceptibility gene. Lynch syndrome also raises risk for particular ovarian histologies. A three-generation history should include ovarian, fallopian-tube, primary peritoneal, breast, pancreatic, prostate, colorectal and endometrial cancers, ages at diagnosis, bilateral disease and ancestry where relevant. Absence of an obvious family history does not exclude inherited susceptibility because families may be small, records incomplete or variants inherited through either parental line.
Reproductive and hormonal associations modify population risk but rarely determine diagnosis in an individual. Nulliparity, infertility and endometriosis are associated with some epithelial subtypes; endometriosis is particularly linked to clear-cell and endometrioid cancers. Obesity and postmenopausal hormone exposure have more modest or subtype-dependent associations. Pregnancy, a functional cyst and benign endometriosis remain much more common explanations for an adnexal finding in reproductive years.
Risk reduction is not equivalent to zero risk. Prior oral-contraceptive use, pregnancy, breastfeeding and risk-reducing salpingo-oophorectomy in appropriately selected high-risk individuals reduce risk, yet primary peritoneal cancer can still occur after surgery. Prophylactic surgery requires genetics-led counselling about timing, fertility, surgical menopause and residual risk; it is not a routine response to anxiety or an isolated CA125 result. A suspected current cancer should enter a diagnostic pathway rather than being managed as risk prevention.
Diagnosis
History
Ask about persistent abdominal distension rather than transient bloating, early satiety, reduced appetite, pelvic or abdominal pain, urinary urgency or frequency, altered bowel habit, fatigue, weight change and unexplained bleeding. Establish duration, frequency, progression and impact. Record age, menopausal status, pregnancy possibility, prior endometriosis or adnexal surgery, personal malignancy, and a three-generation cancer history. Acute severe pain, vomiting or collapse suggests torsion, rupture, haemorrhage or another emergency even when malignancy is possible.
Examination
Assess observations, pallor, hydration, nutritional state and thromboembolic signs. Examine the abdomen for distension, tenderness, a mass, ascites, organomegaly and peritoneal signs. With consent, privacy and a chaperone, pelvic examination may identify a fixed, irregular or nodular mass, cul-de-sac disease or cervical abnormality; a normal examination does not exclude cancer. Look for pleural effusion, supraclavicular nodes and signs of bowel or urinary obstruction when symptoms suggest advanced disease.
Investigations
Pregnancy testing is essential when relevant. Full blood count, renal and liver function, albumin and other tests support fitness and alternative diagnoses. In the current recognition pathway, people aged 40 or over with persistent suggestive symptoms have CA125 measured, followed by age-specific CA125 thresholds for urgent abdominal and pelvic ultrasound; this is UK guidance, not an Indian national rule. Ultrasound should describe morphology, solid components, papillae, septa, vascularity, bilaterality and free fluid. Suspicious findings prompt gynaecological cancer referral. Specialist assessment may add CT chest, abdomen and pelvis, selected tumour markers, biopsy when neoadjuvant treatment is planned, and germline and tumour testing. Do not use CA125 alone to rule cancer in or out.
Differential Diagnosis
A complex adnexal mass may be malignant, borderline, benign, inflammatory, pregnancy-related or non-gynaecological. Benign ovarian causes include functional and haemorrhagic cysts, endometrioma, mature cystic teratoma, serous or mucinous cystadenoma, fibroma and theca-cell lesions. Borderline epithelial tumours lack destructive stromal invasion but still require specialist staging and surveillance. In younger patients, germ-cell tumours and sex-cord stromal tumours alter the marker panel and fertility discussion. Metastatic tumours to the ovary, including gastrointestinal or breast primary disease, can be bilateral and should not be assumed to be a new ovarian primary.
Tubal and pelvic inflammatory disease, tubo-ovarian abscess, hydrosalpinx and genital tuberculosis are important Indian mimics, particularly with pain, fever, infertility or inflammatory findings. Ectopic pregnancy must be excluded whenever pregnancy is possible. Fibroids, retroperitoneal masses, pelvic kidney, appendiceal disease, colorectal cancer, lymphoma and a distended bladder can appear adnexal on incomplete imaging. Ascites may reflect cirrhosis, tuberculosis, heart failure or another cancer.
Symptoms alone are also non-specific. Irritable bowel syndrome, constipation, dyspepsia and urinary infection can cause overlapping complaints, but new persistent symptoms in later life need investigation rather than indefinite symptomatic treatment. CA125 can rise with menstruation, endometriosis, fibroids, pregnancy, infection, liver disease and peritoneal inflammation. Conversely, some ovarian cancers produce little CA125. The diagnostic task is to integrate clinical trajectory, imaging, markers, tissue and disease distribution, not to choose between cancer and benignity from one number.
Management
Immediate management first addresses instability, bowel or urinary obstruction, venous thromboembolism, severe pain, sepsis and nutritional compromise. Once ovarian malignancy is suspected, referral should precede an unplanned operation. A specialist multidisciplinary team reviews imaging, tumour markers, pathology when available, performance status, comorbidity, anaesthetic risk, fertility priorities and the probability of complete cytoreduction. If apparently confined disease is taken to surgery, systematic staging and avoidance of capsule rupture matter because surgical spill changes stage.
For many epithelial cancers, the treatment backbone is surgery and platinum-based chemotherapy. Primary cytoreductive surgery is considered when complete or near-complete macroscopic resection appears feasible with acceptable morbidity. When disease distribution, fitness or operative risk makes that unlikely, image-guided or laparoscopic tissue confirmation may precede neoadjuvant chemotherapy and interval surgery. Early-stage, low-grade, borderline, germ-cell and sex-cord tumours require histology-specific decisions; fertility-sparing surgery is possible only in selected cases with careful staging and counselling.
After response to initial therapy, maintenance choices may depend on BRCA1/2 status, homologous-recombination biology, stage, response and access. Recurrence management considers the interval since platinum exposure, symptoms, prior toxicities, molecular targets, resectability and patient goals. Supportive and palliative care should be integrated early for pain, ascites, nausea, bowel symptoms, fatigue and psychological distress. This guide intentionally avoids naming one universal sequence because licensing, evidence and affordability change, and because regimen selection requires an oncology prescription and current institutional protocol.
Prescribing Information
Anticancer medicines for ovarian cancer are high-risk specialist prescriptions. Common treatment classes include platinum compounds, taxanes, anti-angiogenic therapy, poly(ADP-ribose) polymerase inhibitors and, in selected recurrent disease, other targeted agents or antibody-drug conjugates. Exact selection, dose, schedule, route, premedication and duration depend on histology, stage, body surface area, organ function, molecular findings, prior exposure, performance status and the current oncology formulary. A public educational guide must not convert a trial regimen into a patient-specific prescription.
Before systemic therapy, verify pathology, pregnancy status when relevant, weight, full blood count, renal and liver function, neuropathy, hearing, cardiovascular risk, thrombotic history, concomitant medicines and allergies. Platinum therapy can cause myelosuppression, nausea, hypersensitivity and organ-specific toxicity; taxanes commonly cause neuropathy, alopecia, myelosuppression and infusion reactions. Anti-angiogenic therapy can cause hypertension, proteinuria, bleeding, thrombosis, impaired wound healing and gastrointestinal perforation in susceptible patients. PARP inhibitors can cause fatigue, nausea, anaemia and other cytopenias and require medicine-specific monitoring.
Patients need a written fever and emergency plan. Neutropenic sepsis, uncontrolled vomiting, dyspnoea, chest pain, unilateral leg swelling, bleeding, confusion or severe abdominal symptoms require urgent oncology assessment. Check interactions with anticoagulants, herbal products and over-the-counter medicines. Supportive antiemetics, analgesia, laxatives, thrombosis management and growth-factor use follow individual risk and local policy. Oncology pharmacy verification and documented consent are safety requirements, not administrative extras.
When to Refer
Refer through an urgent gynaecological cancer pathway when ultrasound suggests ovarian cancer, when a complex mass is accompanied by ascites or metastatic features, or when the combined clinical and imaging picture remains suspicious despite an inconclusive marker. The current pathway uses age-specific CA125 thresholds for urgent ultrasound in people aged 40 or over with persistent suggestive symptoms. Those thresholds were developed for the UK pathway and must not be relabelled as Indian national standards. In India, use the receiving cancer centre's criteria and discuss uncertainty directly when access is delayed.
Emergency referral is required for haemodynamic instability, peritonism, suspected torsion or rupture, bowel obstruction, inability to maintain intake, severe uncontrolled pain, sepsis or symptomatic venous thromboembolism. A normal CA125, a prior benign scan or a young age must not delay urgent assessment when the patient is clinically unwell. Adolescents and young adults should reach a centre capable of fertility-preserving oncology care before definitive surgery.
Genetics referral is appropriate for epithelial ovarian, fallopian-tube or primary peritoneal cancer and for unaffected people with a strongly suggestive family history. Referral information should include symptom chronology, menopausal and pregnancy status, examination, laboratory values with dates, imaging reports and preferably images, family history, prior abdominal operations, comorbidities and the patient's language or access needs. Direct clinician-to-clinician discussion is valuable when obstruction, rapidly accumulating ascites or uncertain resectability makes the pathway time-sensitive.
Red Flags
Progressive abdominal enlargement, early satiety, unintentional weight loss, a fixed irregular pelvic mass, ascites, pleural effusion or omental and peritoneal disease on imaging are major cancer warning patterns. New persistent symptoms deserve more weight than a single episode of bloating. A normal CA125 cannot neutralise suspicious imaging, and a raised CA125 cannot establish ovarian origin. Unexplained thrombosis may be a presenting feature of malignancy and warrants assessment of both the thrombotic event and its cause.
Some red flags are emergencies rather than referral cues. Sudden severe unilateral pain with vomiting suggests torsion; collapse, shoulder-tip pain, pallor or hypotension suggests internal bleeding; fever with abdominal tenderness may indicate abscess or sepsis. Persistent vomiting, absolute constipation, distension and colicky pain suggest bowel obstruction. Reduced urine output, flank pain or rising creatinine may signal ureteric obstruction. Dyspnoea may reflect pleural effusion, pulmonary embolism, anaemia or infection. These presentations require stabilization and urgent hospital evaluation before an elective cancer work-up is completed.
During treatment, fever, rigors, confusion, hypotension, mucosal bleeding, new breathlessness, chest pain, unilateral leg swelling, severe diarrhoea, uncontrolled vomiting or escalating abdominal pain require prompt oncology contact. After surgery, wound deterioration, ileus, inability to eat, calf pain or acute dyspnoea are not routine recovery. Safety-netting should name a facility and contact route, specify that delays can be dangerous, and account for travel distance and out-of-hours care.
Indian Clinical Context
GLOBOCAN 2024 estimates a substantial ovarian-cancer burden in India, but diagnostic and treatment capacity varies. A patient may move from a local ultrasound centre to a district hospital and then to a tertiary cancer centre, with repeated tests and loss of time at each hand-off. The safest practical intervention is a complete first referral: symptom trajectory, examination, dated CA125 and other results, structured ultrasound morphology, cross-sectional imaging when already performed, relevant family history and accessible copies of images. Suspicious masses should not be drained or removed in a non-oncology setting merely to obtain a diagnosis.
No single current Indian national ovarian-cancer pathway was identified that supplies universal primary-care CA125 thresholds, operative criteria and drug sequences for every state and institution. This draft therefore uses current recognition guidance for a transparent referral framework and NCI evidence synthesis for disease and treatment principles, while explicitly limiting their jurisdiction. Indian cancer centres and the National Cancer Grid may use institution-specific protocols based on available pathology, genetics, intensive care and medicines. Local governance prevails.
Cost and geography affect choices but do not justify opaque counselling. Explain which tests change treatment, whether genetics results affect relatives, why specialist surgery matters, and what public financing or referral support is actually available. Discuss fertility and surgical menopause before treatment when time permits. Provide counselling in the patient's preferred language, involve a chosen support person with consent, and avoid fatalistic language about advanced disease. Palliative care, nutrition, symptom drainage and psychosocial support are active treatment components at every stage.
NMC Competency Mapping
The NMC 2024 obstetrics and gynaecology curriculum identifies ovarian cancer within gynaecological oncology competency OG34.2. For a graduating learner, the relevant outcome is not independent oncology practice. It is the ability to recognise persistent symptom patterns, take a focused menstrual, reproductive and hereditary-cancer history, examine respectfully, interpret an adnexal ultrasound description, understand the limits of CA125 and arrange appropriate urgent referral. Learners should distinguish epithelial, germ-cell, sex-cord stromal, borderline and metastatic ovarian tumours at a conceptual level.
Clinical reasoning should connect disease biology with the presentation: early peritoneal spread explains ascites, omental disease and bowel symptoms; a distal tubal origin explains why high-grade serous ovarian, fallopian-tube and primary peritoneal cancers are grouped; capsule rupture explains FIGO stage IC1; and age guides the differential and marker strategy. Students should understand the roles of CT, tissue diagnosis, surgical staging, cytoreduction, platinum-based therapy, biomarker testing and genetics without memorising an unverified drug schedule.
Skills should be assessed through supervised history, abdominal and pelvic examination, explanation of investigations, safe handover and an OSCE on referral urgency. Communication includes uncertainty, cancer risk, fertility, consent and family implications. Professional scope requires the learner to avoid reassurance from one normal marker, avoid aspirating a suspicious mass, and escalate acute instability. This draft maps to OG34.2 but does not certify procedural or prescribing competence.
Key Exam Pearls for NEET PG
High-grade serous carcinoma is the common aggressive epithelial pattern and many tumours arise from the fimbrial fallopian tube before involving ovary and peritoneum. Ovarian, fallopian-tube and primary peritoneal high-grade serous cancers are staged and treated together. Persistent bloating or abdominal distension, early satiety, pelvic or abdominal pain and urinary frequency are recognition clues; they are not sufficiently specific to diagnose cancer. CA125 is a monitoring and pathway marker, not an average-risk screening test and not a stand-alone diagnostic test. It rises in benign peritoneal and gynaecological conditions and may be normal in malignancy.
Ultrasound features raising concern include solid components, papillary projections, irregular multilocularity, bilateral suspicious masses, ascites and marked vascularity. CT assesses disease extent after suspicion; definitive staging is surgical when primary surgery is appropriate. FIGO IC1 means surgical spill, so a suspicious mass should be removed intact and not aspirated. Peritoneal washings are obtained before tumour manipulation. Cytoreduction aims to minimise residual macroscopic disease, but primary surgery versus neoadjuvant chemotherapy is an MDT decision.
Platinum and taxane therapy is a common epithelial-cancer backbone; BRCA1/2 and homologous-recombination biology influence maintenance options. Dysgerminoma is a germ-cell tumour seen in younger patients and is highly treatment-sensitive; granulosa-cell tumour may secrete oestrogen; Krukenberg tumour is metastatic, often bilateral, and classically associated with a gastrointestinal primary. Genetics assessment matters even without a dramatic family history. A UK CA125 threshold should never be presented in an exam answer as an Indian national rule unless the question names the guideline.
Frequently Asked Questions
Can a normal CA125 blood result rule out ovarian cancer?
No. Some ovarian cancers do not produce much CA125, particularly at an early stage or in certain histological subtypes. CA125 can also rise in benign endometriosis, menstruation, fibroids, pregnancy, infection, liver disease and other causes of peritoneal inflammation. It must be interpreted with symptoms, age, examination and imaging; suspicious ultrasound findings require referral even when CA125 is normal.
Should an average-risk person have regular ovarian ultrasound screening?
Routine CA125 or ultrasound screening is not recommended for average-risk asymptomatic people because false-positive results can lead to anxiety and unnecessary operations while available strategies have not shown a clear mortality benefit. People with a strong hereditary-cancer history need genetics-led risk assessment, which is different from population screening and may lead to tailored surveillance or risk-reducing surgery discussions.
Why should a suspicious ovarian mass be referred before surgery?
The first operation strongly influences staging accuracy and the opportunity for complete cytoreduction. A specialist team plans washings, intact specimen removal, peritoneal and omental assessment, fertility decisions and any additional procedures. Aspiration or rupture can disseminate cells and upstage apparently confined disease. Referral also ensures suitable pathology, anaesthesia, critical care and postoperative oncology planning are available.
Does ovarian cancer always mean both ovaries and the uterus are removed?
No. Standard surgery for many epithelial cancers is extensive, but the operation depends on histology, stage, disease distribution, age and goals. Carefully selected early-stage germ-cell, sex-cord or some epithelial tumours may permit fertility-sparing surgery after specialist staging and counselling. No clinician should promise fertility preservation before pathology and staging, but nor should it be dismissed without an oncology discussion.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic